Eli Lilly Price to Sales Ratio 2012-2026 | LLY
Historical PS ratio values for Eli Lilly (LLY) over the last 10 years. The current P/S ratio for Eli Lilly as of September 15, 2026 is .
| Eli Lilly P/S Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Sales per Share | Price to Sales Ratio |
| 2026-09-15 | 1136.11 | 12.79 | |
| 2026-06-30 | 1197.71 | $88.84 | 13.48 |
| 2026-03-31 | 916.88 | $80.42 | 11.40 |
| 2025-12-31 | 1069.51 | $72.46 | 14.76 |
| 2025-09-30 | 758.22 | $65.98 | 11.49 |
| 2025-06-30 | 772.95 | $59.03 | 13.09 |
| 2025-03-31 | 817.26 | $54.24 | 15.07 |
| 2024-12-31 | 762.60 | $49.81 | 15.31 |
| 2024-09-30 | 873.71 | $45.20 | 19.33 |
| 2024-06-30 | 891.63 | $43.11 | 20.68 |
| 2024-03-31 | 764.84 | $39.82 | 19.21 |
| 2023-12-31 | 572.09 | $37.82 | 15.13 |
| 2023-09-30 | 526.18 | $35.54 | 14.80 |
| 2023-06-30 | 458.43 | $32.67 | 14.03 |
| 2023-03-31 | 334.83 | $30.64 | 10.93 |
| 2022-12-31 | 355.54 | $31.55 | 11.27 |
| 2022-09-30 | 313.41 | $32.26 | 9.72 |
| 2022-06-30 | 313.24 | $32.01 | 9.78 |
| 2022-03-31 | 275.73 | $32.23 | 8.55 |
| 2021-12-31 | 264.85 | $31.07 | 8.52 |
| 2021-09-30 | 220.83 | $30.45 | 7.25 |
| 2021-06-30 | 218.66 | $29.31 | 7.46 |
| 2021-03-31 | 177.20 | $27.95 | 6.34 |
| 2020-12-31 | 159.48 | $26.92 | 5.92 |
| 2020-09-30 | 139.11 | $25.30 | 5.50 |
| 2020-06-30 | 153.55 | $24.96 | 6.15 |
| 2020-03-31 | 129.13 | $25.02 | 5.16 |
| 2019-12-31 | 121.71 | $23.77 | 5.12 |
| 2019-09-30 | 102.97 | $22.69 | 4.54 |
| 2019-06-30 | 101.44 | $21.90 | 4.63 |
| 2019-03-31 | 118.15 | $21.22 | 5.57 |
| 2018-12-31 | 104.80 | $20.77 | 5.04 |
| 2018-09-30 | 96.69 | $18.42 | 5.25 |
| 2018-06-30 | 76.47 | $18.61 | 4.11 |
| 2018-03-31 | 68.86 | $18.70 | 3.68 |
| 2017-12-31 | 74.61 | $18.92 | 3.94 |
| 2017-09-30 | 75.09 | $21.24 | 3.54 |
| 2017-06-30 | 71.79 | $20.78 | 3.45 |
| 2017-03-31 | 72.90 | $20.37 | 3.58 |
| 2016-12-31 | 63.32 | $19.99 | 3.17 |
| 2016-09-30 | 68.65 | $19.61 | 3.50 |
| 2016-06-30 | 66.93 | $19.37 | 3.45 |
| 2016-03-31 | 60.79 | $18.95 | 3.21 |
| 2015-12-31 | 70.64 | $18.73 | 3.77 |
| 2015-09-30 | 69.72 | $18.45 | 3.78 |
| 2015-06-30 | 69.14 | $18.33 | 3.77 |
| 2015-03-31 | 59.75 | $18.24 | 3.28 |
| 2014-12-31 | 56.34 | $18.24 | 3.09 |
| 2014-09-30 | 52.58 | $18.83 | 2.79 |
| 2014-06-30 | 50.00 | $19.62 | 2.55 |
| 2014-03-31 | 46.95 | $20.50 | 2.29 |
| 2013-12-31 | 40.32 | $21.28 | 1.89 |
| 2013-09-30 | 39.40 | $21.26 | 1.85 |
| 2013-06-30 | 38.10 | $20.79 | 1.83 |
| 2013-03-31 | 43.67 | $20.33 | 2.15 |
| 2012-12-31 | 37.58 | $20.25 | 1.86 |
| 2012-09-30 | 35.75 | $20.34 | 1.76 |
| 2012-06-30 | 31.99 | $21.00 | 1.52 |
| 2012-03-31 | 29.67 | $21.61 | 1.37 |
| 2011-12-31 | 30.24 | $21.81 | 1.39 |
| 2011-09-30 | 26.55 | $21.98 | 1.21 |
| 2011-06-30 | 26.57 | $21.58 | 1.23 |
| 2011-03-31 | 24.59 | $21.17 | 1.16 |
| 2010-12-31 | 24.16 | $20.89 | 1.16 |
| 2010-09-30 | 24.84 | $20.70 | 1.20 |
| 2010-06-30 | 22.48 | $20.65 | 1.09 |
| 2010-03-31 | 23.97 | $20.27 | 1.18 |
| 2009-12-31 | 23.31 | $19.89 | 1.17 |
| 2009-09-30 | 21.26 | $19.25 | 1.10 |
| 2009-06-30 | 21.97 | $18.94 | 1.16 |
| 2009-03-31 | 20.90 | $18.83 | 1.11 |
| 2008-12-31 | 24.86 | $18.62 | 1.33 |
| 2008-09-30 | 26.81 | $18.62 | 1.44 |
| 2008-06-30 | 27.84 | $18.07 | 1.54 |
| 2008-03-31 | 30.82 | $17.61 | 1.75 |
| 2007-12-31 | 31.60 | $17.09 | 1.85 |
| 2007-09-30 | 33.41 | $16.24 | 2.06 |
| 2007-06-30 | 32.55 | $15.59 | 2.09 |
| 2007-03-31 | 31.06 | $14.90 | 2.08 |
| 2006-12-31 | 29.90 | $14.44 | 2.07 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $1071.528B | $65.179B |
| Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Johnson & Johnson (JNJ) | United States | $641.804B | 24.52 |
| AbbVie (ABBV) | United States | $462.493B | 24.08 |
| Merck (MRK) | United States | $357.370B | 45.12 |
| Roche Holding AG (RHHBY) | Switzerland | $349.105B | 0.00 |
| Novartis AG (NVS) | Switzerland | $265.214B | 16.01 |
| Novo Nordisk (NVO) | Denmark | $194.004B | 10.81 |
| Pfizer (PFE) | United States | $157.995B | 9.09 |
| Sanofi (SNY) | France | $105.050B | 8.84 |
| Bayer (BAYRY) | Germany | $56.081B | 9.98 |
| Innoviva (INVA) | United States | $1.510B | 5.16 |